Cargando…

“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas

Detalles Bibliográficos
Autores principales:	Tagliabue, Elda, Campiglio, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235291/ https://www.ncbi.nlm.nih.gov/pubmed/25478327 http://dx.doi.org/10.3389/fonc.2014.00334

Ejemplares similares

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Identification of HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviours
por: Casalini, P, et al.
Publicado: (2001)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Rescue of HER-2-positive breast carcinoma cells from dormancy by growth factors produced during wound healing
por: Agresti, R, et al.
Publicado: (2001)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis
por: Pellegrino, Benedetta, et al.
Publicado: (2020)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells.
por: Tagliabue, E., et al.
Publicado: (1996)

Multiomic analysis of HER2-enriched and AR-positive breast carcinoma with apocrine differentiation and an oligometastatic course: a case report
por: Poggiali, Brando, et al.
Publicado: (2023)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
por: Triulzi, Tiziana, et al.
Publicado: (2015)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
por: Fogazzi, Valentina, et al.
Publicado: (2022)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors
por: Agresti, Roberto, et al.
Publicado: (2019)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

Multi-Omics Approaches in Immunological Research
por: Chu, Xiaojing, et al.
Publicado: (2021)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
por: Lucci, Maria Antonietta, et al.
Publicado: (2010)

Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer
por: Nieder, Carsten, et al.
Publicado: (2017)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
por: Yan, Yan, et al.
Publicado: (2021)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

De-escalated radiotherapy for HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes undergoing anti-HER2 targeted therapy
por: Liu, Jing, et al.
Publicado: (2023)

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer
por: Pellas, Ulrika, et al.
Publicado: (2023)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
por: Yu, Xingfei, et al.
Publicado: (2021)

Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges
por: Stucci, Luigia Stefania, et al.
Publicado: (2022)

Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
por: Chow, Christopher Y.C., et al.
Publicado: (2022)

HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis
por: Egebjerg, Kristian, et al.
Publicado: (2021)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021)

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
por: Wang, Long, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6fvm28do8u25p0va20lc5dabot